Skip to main content
OpenTrials
Completed

NCT Number: NCT05090618

The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kazakhstan

Almaty, 050020, Kazakhstan

About this study

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons of Kazakh nationality
  • Age up to 59 years inclusive at the time of primary myocardial infarction
  • Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
  • Presence of coronary angiography
  • Persons able and willing to provide written informed consent;

Exclusion criteria

  • Age at primary myocardial infarction 60 years and older
  • Heart defects, congenital and acquired
  • Non-ischemic cardiomyopathies
  • Autoimmune diseases
  • Diabetes mellitus at the time of development of primary myocardial infarction
  • Terminal stages of renal and hepatic failure

Treatment and study plan

DNA analysis

Genetic

GWAS

Primary outcomes

  1. number of SNPs associated with Heart Attack

    Time frame: 1 year

    Using GWAS to identify candidate genes associate with Heart Attack

Sponsors and collaborators

Lead sponsor

Asfendiyarov Kazakh National Medical University

Other

Registry information

Official study title

Preventive and Personalized Medicine (2021-2023)

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Oct 25, 2021
Registry last updated
Mar 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.